In March, 2002, TargeGen, Inc. and Merck KGaA entered into a Master Evaluation and License Agreement. This Agreement provides TargeGen® with access to a broad portfolio of intellectual property pertaining to vascular targeting, gene delivery, and certain small molecule inhibitors of vascular permeability.

In June, 2004 TargeGen® executed a Licensing Agreement with CyDex, Inc. which gives TargeGen® certain rights to use CyDex’s Captisol® formulation for TG100-115 and potentially other future TargeGen® compounds. Captisol is designed to improve the solubility characteristics of certain drug molecules. Poor solubility is a common problem in drug development.

In March, 2005, TargeGen® and Wu Xi PharmaTech Co. Ltd. of Shanghai, China, entered into a Manufacturing Agreement for GMP (Good Manufacturing Practices) manufacture of certain TargeGen® drug candidates and intermediates. This Agreement augments collaborations with Wu Xi ongoing since June, 2003, through which TargeGen® continues to access chemistry services in discovery & development including: synthetic intermediates, custom reagents, lead optimization, scale up of potential drug candidates for preclinical testing, standards, process chemistry and raw materials for GMP production.

TargeGen® seeks strategic alliances with multinational pharmaceutical or biotechnology companies for the clinical development and marketing of certain of its portfolio of pipeline drugs. For partnering information, please contact the Business Development Department:

TargeGen Inc.
Attn: Business Development
9380 Judicial Drive
San Diego, CA 92121

Tel. (858) 678-0760
Fax. (858) 678-0762
fuller@targegen.com